Evonik at CPhI China 2012
We turn your pharmaceutical problems into solutions
- Evonik is one of the world’s leading solution providers in the pharmaceutical industry
- And top performers in all disciplines, from synthesis to the formulation of active ingredients
- Booth number E1B08, Shanghai New International Expo Center, June 26-28, 2012
Evonik Industries is bringing its pharma polymers, biomaterials, silica excipients, amino acids, pharmaceutical actives and intermediates thereof as well as high performance chemical catalysts to CPhI 2012 from June 26 to 28 in Shanghai, China.
As a strategic partner and one of the world’s leading solution providers in the pharmaceutical industry, Evonik provides products and solutions throughout many parts of the pharmaceutical value chain ranging from the manufacturing of active pharmaceutical ingredients all the way to formulation and pharmaceutical production.
Proven high quality polymers for controlled release depot injections, medical device applications and oral dosage forms
Evonik provides a variety of biodegradable polymers under the brand names RESOMER® and LAKESHORE BIOMATERIALSTM, most of them made on the basis of lactide and glycolide. The polymers can be used in a wide variety of applications such as parenteral controlled release, bioresorbable medical devices, tissue engineering and regenerative medicine. Evonik offers both standard-grade polymers in stock, and custom polymers designed to your specific requirements. We have facilities and expertise for feasibility studies, formulation and process development, drug delivery formulation analysis, scale-up, clinical supply manufacturing, and commercial production (i.e. aseptic manufacturing and terminal sterilization).
With more than 50 years of formulation experience, the EUDRAGIT® product portfolio is the pharmaceutical industry’s preferred choice for functional coatings. The intelligent protective and release mechanisms of the EUDRAGIT® pharmaceutical polymers ensure that the active ingredients in tablets and capsules act at the right time and the right place in the gastrointestinal tract. The most recent research successes are melt extrusion, a technology platform that can improve the bioavailability of poorly soluble active ingredients, and the modular drug delivery system (MDD) which can be used to improve the bioavailability of BCS class III and IV drugs as well as to enable oral products for biopharmaceuticals.
Rexim® – expert of amino acid from Europe
Evonik will also exhibit its Rexim® amino acids, peptides, and amino acid derivatives, which are mainly used for parenteral nutrition, as active pharmaceutical ingredients or as versatile building blocks for chiral pharma syntheses.
As a fundamental role in our lives, amino acids make up the proteins that in turn make up much of human and animal tissue, and they are key to ensuring cell growth, repair, and maintenance – that we at Rexim value quality above all, in our products and processes, in our services, and in the relationship we build with our customers.
Pharmaceutical actives and intermediated
In addition, as a leading custom manufacturing partner, Evonik provides proprietary advanced intermediates and APIs, from the clinical stage all the way to commercialization. Evonik’s strengths in exclusive synthesis are high-performance research department, broad technical portfolio covering numerous chemical and biological technologies, experience in handling high-potency active ingredients, and a global FDA-certified production network.
Glidants and processing aids promotes the flowability in tableting Evonik offers a broad range of colloidal silicone dioxide excipients with for improved processes and products in pharmaceutical industry: better powder flow, improved compact properties, tabletting of liquid APIs.
At this year’s CPhI, Evonik will display its latest silica products with pharmaceutical grades: AEROSIL® 200, AEROSIL® R972, AEROSIL® 200 VV and AEROPERL® 300.
All of these products are manufactured according to International Pharmaceutical Excipient Council (IPEC) GMP guidelines for bulk pharmaceutical excipients, tested and certified to compendial methods.
High performance catalysts customized for pharmaceutical synthesis
Life sciences and fine chemicals segment is one of three main markets in focus for the Catalysts Business Line of Evonik, a vital component of this being our pharma application. Our extensive portfolio of Precious Metal Powder Catalysts (PMPC) is ideally suited for the synthesis of pharmaceuticals, fine chemicals and industrial chemicals. Performance criteria such as high selectivity, activity and filterability are demanded.
Therefore, our PMPC catalyst production facility in Shanghai-Xinzhuang has recently achieved ISO 9001 certification enabling us to supply the Chinese market with high quality products straight from a local source. Evonik Catalysts applied technology experts have been working hard in close cooperation with client R&D and production teams to ensure that we meet client requirements. Our wide customer base has benefited from these efforts along with additional services such as custom packaging and precious metal recovery.
In addition to Precious Metal Powder Catalysts, Evonik will also exhibit its Activated Base Metal Catalysts (ABMC), which is known as skeletal catalysts for slurry type reactions that are carried out in batch or semibatch mode, used in the pharmaceuticals and food industries, as well as in fine and industrial chemicals.
For more information, please visit www.evonik.com/pharma
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2011 more than 33,000 employees generated sales of around €14.5 billion and an operating profit (EBITDA) of about €2.8 billion.
Evonik Industries has been producing specialty chemical products in the Greater China region (Mainland China, Hong Kong and Taiwan) since the late1970’s; with wide-ranging trading relations already in place prior to this in the region. Evonik regards Greater China as one of the driving forces of the global economy and we consequently endeavour to grow our business in the region. The company now has around 3,500 employees in the Greater China region, the regional sales reached over 1.2 billion in 2011.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.